var data={"title":"Polyethylene glycol electrolyte solution and sulfate solution kit (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Polyethylene glycol electrolyte solution and sulfate solution kit (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/539190?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=polyethylene-glycol-electrolyte-solution-and-sulfate-solution-kit-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Polyethylene glycol electrolyte solution and sulfate solution kit (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20224039\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Suclear&trade; [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16137803\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Laxative, Osmotic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20224152\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b> Suclear has been discontinued in the US for more than 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bowel cleansing prior to colonoscopy:</b> Oral: May be administered as the <i>split-dose (2-day) regimen</i> (preferred method) or the <i>day-before (1-day) regimen</i> (alternative method).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Split-dose (2-day) regimen:</i> Total volume of liquid consumed over the course of treatment: 3440 mL (~115 oz)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dose 1: Evening before colonoscopy (10-12 hours prior to Dose 2): Dilute the contents of the 6-ounce oral solution bottle to a final volume of 480 mL (16 oz), and drink the contents within 20 minutes. Refill container with 16 ounces of water and drink over the next 2 hours. Refill the container with the second refill of 16 oz of water, and finish drinking before bedtime (2 refills totaling 960 mL [32 oz]). Total volume of liquid consumed with Dose 1: 1440 mL (48 oz).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dose 2: Morning of the colonoscopy (beginning at least 3.5 hours prior to colonoscopy): Drink the entire contents of the reconstituted powder which has been diluted to a final volume of 2000 mL (2 L [~67 oz]) as follows: Using the 16-ounce container provided, drink at a rate of 480 mL (16 oz) every 20 minutes (four 16-ounce containers over ~1.5 hours). Complete at least 2 hours prior to colonoscopy. Total volume of liquid consumed with Dose 2: 2000 mL (~67 oz)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Day-before (1-day) regimen:</i> Total volume of liquid consumed over the course of treatment: 3440 mL (~115 oz)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dose 1: Evening before colonoscopy (beginning at least 3.5 hours prior to bedtime): Drink the diluted contents of the 6-ounce oral solution bottle, which has been further diluted to a final volume of 480 mL (16 oz), preferably within 20 minutes. Refill container with 480 mL (16 oz) of water, and drink over the next 2 hours. Total volume of liquid consumed with Dose 1: 960 mL (32 oz).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dose 2: Evening before colonoscopy (~2 hours after starting Dose 1): Drink the entire contents of the reconstituted powder which has been diluted to a final volume of 2000 mL (2 L [~67 oz]) as follows: Using the 16-ounce container provided, drink at a rate of 480 mL (16 oz) every 20 minutes (four 16-ounce containers over ~1.5 hours). Refill the container with 480 mL (16 oz) of water and finish drinking before bedtime. Total volume of liquid consumed with Dose 2: 2480 mL (~83 oz).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20855999\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20224153\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in manufacturer&rsquo;s labeling (safety has not been adequately studied); however, use caution and ensure adequate hydration in patients with renal impairment or at risk for impairment. Moderate renal impairment (CrCl 30-49 mL/minute) resulted in a 43% higher C<sub>max</sub> and a 16% lower urinary clearance of serum sulfates compared to healthy patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20224154\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20223590\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kit, Oral [each kit contains]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Suclear: Powder for solution, oral: PEG 3350 210 g, sodium bicarbonate 2.86 g, sodium chloride 5.6 g, potassium chloride 0.74 g (2000 mL [DSC]) [contains cherry, lemon-lime, orange, and pineapple flavor packs]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Suclear: Solution, oral: Sodium sulfate 17.5 g, potassium sulfate 3.13 g, and magnesium sulfate 1.6 g (177 mL [DSC]) [contains sodium benzoate]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20224097\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49909924\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Suclear has been discontinued in the US for more than 1 year.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16137976\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM337734.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5WMdul929EOwWceGe3NpnPeg==&amp;TOPIC_ID=88098\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM337734.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20224199\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Each bottle must be diluted prior to use. The entire contents should be consumed followed by each postdose hydration amount, as directed depending on the regimen. Only clear liquids should be consumed from the start of the dosing regimen until 2 hours prior to colonoscopy; thereafter, nothing should be consumed until after colonoscopy. Patients should avoid solid foods, red and purple liquids, milk, and alcoholic beverages on the day prior and the day of the colonoscopy. Oral medications should not be administered within 1 hour of start of therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16137804\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Bowel cleansing prior to colonoscopy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20224095\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Suclear&trade; may be confused with Suprep&reg; Bowel Prep Kit</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20233458\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Malaise (62% to 69%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal distension (52%), nausea (42% to 46%), abdominal pain (38% to 40%), vomiting (11% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum bilirubin (8% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal insufficiency (9% to 25%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Acidosis (3% to 10%), hypercalcemia (4% to 9%), increased serum glucose (2% to 7%), hyperuricemia (4% to 6%), hypokalemia (4%), decreased serum bicarbonate (3% to 4%), increased urine osmolality (2% to 4%), hypophosphatemia (&le;3%), hypochloremia (1%), hyponatremia (&le;1%), decreased serum magnesium (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Increased creatine phosphokinase (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (1% to 2%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20224102\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to sodium sulfate, potassium sulfate, magnesium sulfate, polyethylene glycol or any component of the formulation; GI obstruction, bowel perforation, gastric retention, ileus, toxic colitis, toxic megacolon</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20224103\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Arrhythmias: Serious arrhythmias have occurred rarely with the use of osmotic laxative products; use caution in patients at increased risk for cardiac arrhythmias (eg, recent MI, uncontrolled arrhythmias, unstable angina, cardiomyopathy, history of prolonged QT, HF); consider pre-dose and post-colonoscopy ECGs in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluid and electrolyte abnormalities: Fluid and electrolyte disturbances can lead to arrhythmias, seizures, and renal impairment. Advise patients to maintain adequate hydration before, during, and after treatment. If patient becomes dehydrated or experiences significant vomiting after treatment, consider post-colonoscopy laboratory tests (electrolytes, creatinine, and BUN). Instruct patients to avoid alcohol beginning the day before colonoscopy and until after the completion of the colonoscopy; alcohol consumption may increase risk of dehydration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI effects: Osmotic laxatives may produce colonic mucosal aphthous ulcerations, including cases of ischemic colitis requiring hospitalization. Concomitant use of stimulant laxatives and this preparation may increase the risk and should be avoided. Use caution when interpreting colonoscopy results in patients with known or suspected inflammatory bowel disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Seizures associated with electrolyte abnormalities (eg, hyponatremia, hypokalemia) and low serum osmolality have occurred; use with caution in patients with underlying electrolyte disturbances and in patients at increased risk for seizures (eg, concomitant medications that lower seizure threshold, withdrawal from alcohol or benzodiazepines).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gout: May cause transient increases in uric acid; use caution in patients with gout.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Impaired gag reflex: Observe unconscious or semiconscious patients with impaired gag reflex or those who are otherwise prone to regurgitation or aspiration during administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use caution in patients with renal impairment; adequate hydration is particularly important in these patients or in patients receiving concomitant medications that may affect renal function (eg, diuretics, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, NSAIDs). Consider baseline and post-colonoscopy electrolytes, creatinine, and BUN levels in patients at increased risk for renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ulcerative colitis: Use with caution in patients with severe, active ulcerative colitis; increased risk of exacerbation of ulcerative colitis with use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Evaluate patients with symptoms of bowel obstruction/perforation (nausea, vomiting, abdominal pain or distension) prior to use. Each bottle must be diluted with water prior to use; inadvertent administration of undiluted solution may increase the risk of nausea, vomiting, and fluid/electrolyte abnormalities.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20224098\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20224099\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20224101\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if the components from this preparation are excreted into breast milk. The manufacturer recommends that caution be used if administered to breast-feeding women. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20224118\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Patient should not eat solid food from start of solution administration until after colonoscopy. Patient may have clear liquids (no solid food or milk) until 2 hours prior to colonoscopy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20224206\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Consider baseline and postprocedure labwork (eg, electrolytes, BUN, creatinine) in patients at risk for renal impairment, seizure, or who have a history of electrolyte abnormality; post-colonoscopy labwork (electrolytes, creatinine, and BUN) is recommended in any patient experiencing significant vomiting or signs of dehydration following use. ECG (prior to therapy and post-colonoscopy) in patients with risks for prolonged QT or arrhythmias.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20224109\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Induces catharsis by the osmotic effects of the unabsorbed sulfate salts and polyethylene glycol (PEG) in the GI tract. Specifically, sulfate salts provide sulfate anions, which are poorly absorbed, and PEG, which is primarily unabsorbed, causes water to be retained in the GI tract resulting in watery diarrhea. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20224111\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Moderate renal impairment (CrCl 30-49 mL/minute) resulted in a 43% higher C<sub>max</sub> and a 16% lower urinary clearance of serum sulfates compared to healthy patients</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: PEG 3350: Minimal; Sulfates: Poor; ~20% absorbed systemically</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Serum sulfate: 8.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Serum sulfate: ~5.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces/rectal effluent (primary route of excretion for unabsorbed sulfates and PEG); urine (predominant route for absorbed sulfates and PEG)</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"topicVersionRevision\">Topic 88098 Version 36.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F20224039\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F16137803\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F20224152\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F20855999\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F20224153\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F20224154\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F20223590\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F20224097\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F49909924\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F16137976\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F20224199\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F16137804\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F20224095\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F20233458\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F20224102\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F20224103\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F20224098\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F20224099\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20224101\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F20224118\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F20224206\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F20224109\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F20224111\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/88098|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=polyethylene-glycol-electrolyte-solution-and-sulfate-solution-kit-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Polyethylene glycol electrolyte solution and sulfate solution kit (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}